SOURCE: bioRASI

June 25, 2008 09:00 ET

OncoMune Recruits FAU Research Professor as CSO

Christopher J. Dougherty, Ph.D., Will Lead the Company's Development of Cancer Vaccines and siRNA Therapeutics

MIAMI, FL--(Marketwire - June 25, 2008) - OncoMune, a leader in targeted cancer therapeutics, today announced the appointment of Dr. Christopher J. Dougherty, Ph.D., Research Professor at Florida Atlantic University (FAU), as Chief Scientific Officer.

"It is my pleasure to welcome Dr. Dougherty to our exciting team of immunologists, drug developers, and molecular biologists," said Dr. Boris Reznik, Chairman of OncoMune. "Dr. Dougherty has made many scientific advances in cellular biology as a member of the Research Faculty in the College of Biomedical Science at Florida Atlantic University. We are eager to add his talents and experience as we continue to develop cancer vaccines and RNA interference based therapeutics."

OncoMune is in advanced preclinical development of its therapeutic pipeline, including immunology-based cancer targeting approaches such as the OCM-111 cancer vaccine, as well as its RNA interference and small molecule development programs.

"It is an honor to work under the leadership of Dr. Reznik, in a venture that offers real hope to the millions battling cancer. As an entrepreneur, Dr. Reznik has successfully built numerous companies such as Optum and bioRASI. I am especially excited about joining OncoMune because its therapeutic pipeline is directed against an incredibly powerful target which has been identified in all cancers tested," said Dr. Dougherty. Dr. Dougherty is the primary author of a recently published journal article, "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS," featured in the May 23rd issue of Biochemical and Biophysical Research Communications.

Dr. Dougherty has a doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine, where he also conducted postdoctoral research before working in industry and later joining Florida Atlantic University. He has previously been awarded an American Heart Association fellowship for targeted vascular gene transfer in diabetic models of oxidative stress.

About OncoMune

OncoMune is a late preclinical stage biotechnology company that is developing potentially non-toxic, selective and targeted approaches for treating various forms of cancer. The lead vaccine candidate, OCM-111, has demonstrated efficacy in a series of in vivo experiments and is currently undergoing IND enabling studies for early 2009 clinical trials. Other therapeutic candidates are in different stages of preclinical development. By pioneering the development of multiple vaccines, siRNA and small molecule drugs against the epigenetic cancer-causing transcription factor, BORIS, OncoMune is poised to become a leading player in the rapidly growing field of targeted cancer therapeutics.

Contact Information